Arrowstreet Capital Limited Partnership Has $421.50 Million Stock Position in Cencora, Inc. $COR

Arrowstreet Capital Limited Partnership increased its position in Cencora, Inc. (NYSE:COR) by 22.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,247,968 shares of the company’s stock after purchasing an additional 229,291 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Cencora were worth $421,501,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COR. United Bank increased its position in Cencora by 4.5% in the second quarter. United Bank now owns 7,032 shares of the company’s stock worth $2,109,000 after purchasing an additional 305 shares during the period. Nebula Research & Development LLC acquired a new stake in Cencora in the second quarter worth about $595,000. Treasurer of the State of North Carolina increased its position in Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after purchasing an additional 6,244 shares during the period. Diversify Advisory Services LLC increased its position in Cencora by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after purchasing an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of Cencora by 26.0% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after buying an additional 15,154 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Cencora stock opened at $281.56 on Friday. The firm has a market capitalization of $54.78 billion, a P/E ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The business has a 50-day moving average of $289.22 and a 200-day moving average of $327.63. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter last year, the firm earned $4.42 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has authorized a stock buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is 18.40%.

Wall Street Analysts Forecast Growth

COR has been the subject of several analyst reports. Robert W. Baird decreased their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday, May 8th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday. Citigroup decreased their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.